Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?

dc.contributor.authorDurur-Subasi, Irmak
dc.contributor.authorKose, Duygu
dc.contributor.authorYayla, Muhammed
dc.contributor.authorSirin, Busra
dc.contributor.authorKaraman, Adem
dc.contributor.authorCalik, Ilknur
dc.contributor.authorAlper, Fatih
dc.date.accessioned2026-08-12T18:07:13Z
dc.date.issued2021
dc.departmentFırat Üniversitesi
dc.description.abstractBackground We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. Methods Forty-eight Wistar albino rats were assigned to eight groups (n = 6 x 8). No medication was administered to group I (controls); glycerol (intramuscular injection of 25% glycerol, 10 mL/kg) group II; intravenous iohexol 10 mL/kg to group III; glycerol and iohexol to group IV; iohexol and intraperitoneal levosimendan 0.25 mg/kg to group V; glycerol, iohexol, and levosimendan 0.25 mg/kg to group VI; iohexol and levosimendan 0.5 mg/kg to group VII; and glycerol, iohexol, and levosimendan 0.5 mg/kg to group VIII. One-day water withdrawal and glycerol injection prompted renal damage; iohexol encouraged nephrotoxicity; levosimendan was administered 30 min after glycerol injection and continued on days 2, 3, and 4. The experiment was completed on day 5. Serum blood urea nitrogen (BUN) and creatinine levels, superoxide dismutase (SOD) activity, glutathione (GSH), malondialdehyde (MDA) levels, tumour necrosis factor-alpha (TNF-alpha), nuclear factor kappa ss (NFK-ss), interleukin 6 (IL-6), and histopathological marks were assessed. One-way analysis of variance and Duncan's multiple comparison tests were used. Results Levosimendan changed serum BUN (p = 0.012) and creatinine (p = 0.018), SOD (p = 0.026), GSH (p = 0.012), and MDA (p = 0.011). Levosimendan significantly downregulated TNF-alpha (p = 0.022), NFK-ss (p = 0.008), and IL-6 (p = 0.033). Histopathological marks of hyaline and haemorrhagic cast were improved in levosimendan-injected groups. Conclusion Levosimendan showed nephroprotective properties due to its vasodilator, oxidative distress decreasing and inflammatory cytokine preventing belongings.
dc.identifier.doi10.1186/s41747-021-00249-7
dc.identifier.issn2509-9280
dc.identifier.issue1
dc.identifier.orcid0000-0003-3122-4499
dc.identifier.orcid0000-0002-3091-0609
dc.identifier.orcid0000-0002-9483-8861
dc.identifier.pmid34786647
dc.identifier.scopus2-s2.0-85119116485
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/s41747-021-00249-7
dc.identifier.urihttps://hdl.handle.net/11508/62620
dc.identifier.volume5
dc.identifier.wosWOS:000719317200001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringernature
dc.relation.ispartofEuropean Radiology Experimental
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectContrast media
dc.subjectDrug-related side effects and adverse reactions
dc.subjectIohexol
dc.subjectLevosimendan
dc.subjectRats (Wistar)
dc.titleDoes the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
dc.typeArticle

Dosyalar